Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

43.13 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor (SMI) in preclinical models of ALL and AML 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Via Benzinga
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Kymera Therapeutics to Participate in Upcoming June Investor Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Growth Stocks That Could Double Your Money in 2023
For investors that really want to roll the dice, these are the enticing growth stocks that could double your money. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Join These Motley Fool Investors for "The Market Cap Game Show"
Multiplying the number of shares by the share price is just step one. 
Via The Motley Fool
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
X-Chem and Kymera Expand Existing Partnership
From X-Chem
Via Business Wire
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Perfect Presents to Gift Your 2023 Stock Portfolio
As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023. 
Via InvestorPlace
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month. 
Via InvestorPlace
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
Why Is SOFI Stock Up 7% Today?
SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.